Forensic Technologies And Services MarketSize, Share & Industry Analysis, 2026-2034By TypeBy LocationBy ApplicationBy OfferingBy End User

Forensic technologies and services cover the instruments, reagents, software and laboratory and field services used to collect, process and interpret biological and trace evidence for criminal investigation, biodefense surveillance and pharmacogenetic testing. The category spans laboratory-based platforms such as capillary electrophoresis and next generation sequencing alongside portable field devices, plus the consumables, case-management software and analytical services that accompany them. Buyers include public and private forensic laboratories, law enforcement and crime investigation departments, hospitals and diagnostic centers, and academic and research institutes.

USD 7.85 billion of revenue was recorded in the global forensic technologies and services market in 2025. By 2034 the figure reaches USD 17.27 billion, a compound annual growth rate of 9.11% through the forecast period, along a series that runs USD 5.1 billion in 2020, USD 7.2 billion in 2024, USD 8.6 billion in 2026 and USD 12.37 billion in 2030.

31.97% of 2025 revenue sits in Capillary Electrophoresis, worth USD 2.51 billion and rising to USD 4.84 billion at 28.02% by 2034, the largest type line in both years. Growth is fastest in Next Generation Sequencing (NGS) at 14.58% and slowest in Polymerase Chain Reaction (PCR) at 6.1%. The lines gaining share are Next Generation Sequencing (NGS) and Rapid DNA Analysis. Capillary Electrophoresis, Polymerase Chain Reaction (PCR), Automated Liquid Handling Technology, Microarrays and Others lose share without losing revenue.

By location, Laboratory Forensic Technology accounts for 77.96% of 2025 revenue at USD 6.12 billion, reaching USD 11.74 billion and 67.98% by 2034. Portable Forensic Technology grows faster at 13.78% against 7.51%, moving from 22.04% of revenue to 32.02% by 2034. This axis divides the same revenue as the type split instead of adding to it, so the two are read together and never summed.

North America is the largest region at 37.83% of 2025 revenue, worth USD 2.97 billion and reaching USD 5.87 billion by 2034. Europe follows at 26.88%, moving from USD 2.11 billion to USD 4.32 billion, and Middle East and Africa is the smallest at 5.86%. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, seven type lines and five segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 7.85 billion in 2025 to USD 17.27 billion in 2034, a compound annual rate of 9.11%, having reached USD 7.2 billion in 2024 from USD 5.1 billion in 2020.
• The largest line by type is Capillary Electrophoresis, worth USD 2.51 billion and 31.97% of revenue in 2025, rising to USD 4.84 billion and 28.02% by 2034.
• Next Generation Sequencing (NGS) is the fastest-growing line at 14.58%, lifting its share from 14.01% in 2025 to 22% in 2034 and its revenue from USD 1.1 billion to USD 3.8 billion.
• Against a base case of USD 17.27 billion in 2034, the study also reports a bear case at USD 15.46 billion and a bull case at USD 19.69 billion, with the assumptions behind each set out separately.
• The largest region is North America, generating USD 2.97 billion in 2025 (37.83% of the global total) and USD 5.87 billion by 2034, ahead of Europe at 26.88%.
• The United States accounts for 78.11% of North America in the base year, worth USD 2.32 billion in 2025 and reaching USD 4.46 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global forensic technologies and services market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 9.11% rate carrying the total.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

Composition shifts on the type axis. Next Generation Sequencing (NGS) grows at 14.58% across 2026-2034 against 6.1% for Polymerase Chain Reaction (PCR), the widest spread on the type axis. Over the forecast period that moves Next Generation Sequencing (NGS) from 14.01% of revenue to 22%, and Polymerase Chain Reaction (PCR) from 27.01% to 21.02%. In absolute terms Next Generation Sequencing (NGS) rises from USD 1.1 billion to USD 3.8 billion, while Polymerase Chain Reaction (PCR) rises from USD 2.12 billion to USD 3.63 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Asia Pacific and Latin America gain regional share. Asia Pacific moves from 23.18% of revenue in 2025 to 29.01% in 2034, worth USD 1.82 billion rising to USD 5.01 billion; Latin America moves from 6.24% of revenue in 2025 to 6.49% in 2034, worth USD 0.49 billion rising to USD 1.12 billion. The remaining regions grow in absolute terms while giving up share: North America at 37.83% moving to 33.99%, Europe at 26.88% moving to 25.01%, Middle East and Africa at 5.86% moving to 5.5%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Year by year the total runs USD 5.1 billion in 2020, USD 7.2 billion in 2024, USD 7.85 billion in 2025, USD 8.6 billion in 2026, USD 12.37 billion in 2030 and USD 17.27 billion in 2034. There is no discontinuity to time, and 9.11% forecast growth against 9.01% historical means the trend continues and does not turn. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.

Next Generation Sequencing (NGS) carries the market's growth rate

The 9.11% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

Downside case: USD 15.46 billion by 2034, against USD 17.27 billion in the base case

What the bull case turns on

Concentration on the type axis

North America holds 37.83% of the global forensic technologies and services market in 2025, worth USD 2.97 billion rising to USD 5.87 billion in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 33.99%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Capillary Electrophoresis leads here as it does globally, at 31.97% of 2025 revenue, and Next Generation Sequencing (NGS) again grows fastest at 14.58%. The full report breaks North America out along every axis and by country.

The largest single market in North America is the United States, at USD 2.32 billion in 2025 and USD 4.46 billion in 2034. At 78.11% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Against regional totals of USD 2.97 billion in 2025 and USD 5.87 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in the United States is the global one: 31.97% of 2025 revenue in Capillary Electrophoresis, 28.02% by 2034, against 14.58% growth in Next Generation Sequencing (NGS) taking it from 14.01% to 22%. Because the country carries 78.11% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports the United States by type separately.

In the United States, forensic technologies and services are governed less by product approval than by laboratory accreditation and evidentiary standards. Bodies such as the ANSI National Accreditation Board assess forensic laboratories against ISO/IEC competence standards, and facilities conducting DNA analysis must additionally satisfy the FBI's Quality Assurance Standards to contribute profiles to the national CODIS database. The National Institute of Standards and Technology, through its Organization of Scientific Area Committees, publishes consensus guidance on digital evidence handling, pattern evidence and forensic reporting methods. A supplier's instruments and software are judged chiefly on whether they support a laboratory's accreditation status and courtroom admissibility standing.

Competition in the United States runs between the suppliers this study tracks: Agilent Technologies, Promega, QIAGEN, LGC Forensics, MSAB, AB Sciex (Danaher Corporation), Eurofins Medigenomix GmbH, Forensics Consulting Solutions, Forensic Pathways, GE Healthcare Lifescience, LGC Limited, Neogen Corporation, NMS Labs, Pyramidal Technologies Ltd., SPEX Forensics and Thermo Fisher Scientific, Inc.. Two different problems sit on the same axis: holding Capillary Electrophoresis at 31.97% of 2025 revenue, and taking Next Generation Sequencing (NGS) while it grows at 14.58%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

5.35% of global revenue is generated in Canada; USD 0.42 billion in 2025, reaching USD 0.82 billion in 2034, and 14.14% of North America.

In Europe, 26.88% of global revenue puts 2025 at USD 2.11 billion on the way to USD 4.32 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

Share settles at 25.01% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Capillary Electrophoresis largest at 31.97% of 2025 revenue, Next Generation Sequencing (NGS) fastest at 14.58%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

27.96% of Europe's base-year revenue comes from Germany; USD 0.59 billion, rising to USD 1.17 billion by 2034. Its 27.96% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 2.11 billion and USD 4.32 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

The type pattern in Germany is the global one: 31.97% of 2025 revenue in Capillary Electrophoresis, 28.02% by 2034, against 14.58% growth in Next Generation Sequencing (NGS) taking it from 14.01% to 22%. Since 27.96% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for Germany appears on its own in the full report.

German forensic technologies and services fall under a layered regime combining German criminal procedure law, EU product rules and accreditation. Forensic DNA analysis is governed by the German Genetic Fingerprinting Act and the Code of Criminal Procedure, which set out when profiling is permitted and how samples and data are handled. Laboratories seeking recognition by police and courts obtain accreditation from the national accreditation body, DAkkS, against international laboratory competence standards. Instruments incorporating measurement or electronic functions must also carry CE marking under the applicable EU conformity regime, and any personal data processed during forensic work falls within the scope of the General Data Protection Regulation. Suppliers therefore need to demonstrate both technical conformity and lawful handling of forensic data before their tools see courtroom use.

Competition in Germany runs between the suppliers this study tracks: Agilent Technologies, Promega, QIAGEN, LGC Forensics, MSAB, AB Sciex (Danaher Corporation), Eurofins Medigenomix GmbH, Forensics Consulting Solutions, Forensic Pathways, GE Healthcare Lifescience, LGC Limited, Neogen Corporation, NMS Labs, Pyramidal Technologies Ltd., SPEX Forensics and Thermo Fisher Scientific, Inc.. The commercially relevant division is 31.97% of 2025 revenue in Capillary Electrophoresis, where the volume is, against 14.58% growth in Next Generation Sequencing (NGS), where share moves. Weighting toward Europe means competing for 26.88% of 2025 global revenue, a base of USD 2.11 billion moving to USD 4.32 billion across the forecast period.

6.5% of global revenue is generated in the United Kingdom; USD 0.51 billion in 2025, reaching USD 0.99 billion in 2034, and 24.17% of Europe.

France is sized at USD 0.34 billion in 2025, rising to USD 0.69 billion by 2034; 4.33% of global revenue and 16.11% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 23.18% of global revenue puts 2025 at USD 1.82 billion rising to USD 5.01 billion in 2034. Among the five regions it ranks third by revenue in both years.

By 2034 the share has moved up to 29.01%, so the region grows faster than the market's 9.11% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 31.97% of 2025 revenue in Capillary Electrophoresis, fastest growth of 14.58% in Next Generation Sequencing (NGS). The full report breaks Asia Pacific out along every axis and by country.

USD 0.62 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 1.6 billion by 2034. Its 34.07% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 1.82 billion and USD 5.01 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

The type pattern in China is the global one: 31.97% of 2025 revenue in Capillary Electrophoresis, 28.02% by 2034, against 14.58% growth in Next Generation Sequencing (NGS) taking it from 14.01% to 22%. Because the country carries 34.07% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by type for China is reported separately in the full report.

In China, forensic technologies and services sit within the judicial expertise system overseen by the Ministry of Justice, with the Ministry of Public Security setting standards for criminal investigation laboratories. Institutions offering forensic examination services must hold judicial authentication qualification under the Administrative Measures for Judicial Expertise, and testing laboratories typically seek accreditation from the China National Accreditation Service for Conformity Assessment against recognised competence standards. Instruments sold into this market may also require certification under the compulsory product certification scheme where they qualify as regulated equipment. Because forensic findings feed directly into criminal proceedings, examiners and their laboratories are expected to maintain documented chains of custody and methodological consistency that satisfy both accrediting bodies and the courts that rely on their conclusions.

Competition in China runs between the suppliers this study tracks: Agilent Technologies, Promega, QIAGEN, LGC Forensics, MSAB, AB Sciex (Danaher Corporation), Eurofins Medigenomix GmbH, Forensics Consulting Solutions, Forensic Pathways, GE Healthcare Lifescience, LGC Limited, Neogen Corporation, NMS Labs, Pyramidal Technologies Ltd., SPEX Forensics and Thermo Fisher Scientific, Inc.. Volume sits in Capillary Electrophoresis at 31.97% of 2025 revenue; movement sits in Next Generation Sequencing (NGS) at 14.58% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 1.82 billion in 2025 reaching USD 5.01 billion by 2034, 23.18% of global revenue at the start of that period.

Within Asia Pacific, Japan accounts for 21.98% of regional revenue and 5.1% of the global total, worth USD 0.4 billion in 2025 and USD 1 billion by 2034.

Within Asia Pacific, India accounts for 14.84% of regional revenue and 3.44% of the global total, worth USD 0.27 billion in 2025 and USD 0.9 billion by 2034.

Latin America holds 6.24% of the global forensic technologies and services market in 2025, worth USD 0.49 billion and reaches USD 1.12 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share climbs to 6.49% by 2034, because it outgrows the market's 9.11%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Capillary Electrophoresis largest at 31.97% of 2025 revenue, Next Generation Sequencing (NGS) fastest at 14.58%. Latin America is reported axis by axis and country by country in the full study.

Brazil is the largest market within Latin America, generating USD 0.25 billion in 2025 and projected to reach USD 0.56 billion by 2034. It accounts for 51.02% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.49 billion to USD 1.12 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Capillary Electrophoresis at 31.97% of 2025 revenue, easing to 28.02% by 2034, and the fastest is Next Generation Sequencing (NGS) at 14.58%, from 14.01% to 22%. Its 51.02% weight in Latin America means those movements carry straight into the regional totals. Per-type revenue for Brazil appears on its own in the full report.

Brazilian forensic technologies and services are shaped by federal and state institutions rather than a single national regulator. Criminalística units attached to state civil and federal police forces conduct forensic examinations under procedural rules set by Brazilian criminal law, and forensic genetics work intersects with the national DNA profile database legislation governing collection, storage and comparison of genetic samples. Laboratories pursuing formal recognition seek accreditation from Cgcre, the accreditation arm of Inmetro, against international laboratory competence standards. Where forensic equipment overlaps with medical or diagnostic device categories, such as toxicology or imaging instruments, ANVISA's health surveillance rules on registration and quality management can also apply, adding a further conformity layer suppliers must satisfy before equipment enters routine forensic use.

Agilent Technologies, Promega, QIAGEN, LGC Forensics, MSAB, AB Sciex (Danaher Corporation), Eurofins Medigenomix GmbH, Forensics Consulting Solutions, Forensic Pathways, GE Healthcare Lifescience, LGC Limited, Neogen Corporation, NMS Labs, Pyramidal Technologies Ltd., SPEX Forensics and Thermo Fisher Scientific, Inc. are the suppliers covered in Brazil. The commercially relevant division is 31.97% of 2025 revenue in Capillary Electrophoresis, where the volume is, against 14.58% growth in Next Generation Sequencing (NGS), where share moves. The commercial size of that position is USD 0.49 billion in 2025 and USD 1.12 billion by 2034, 6.24% of the global total in the base year.

Within Latin America, Mexico accounts for 30.61% of regional revenue and 1.91% of the global total, worth USD 0.15 billion in 2025 and USD 0.34 billion by 2034.

5.86% of the global forensic technologies and services market sits in Middle East and Africa in 2025, worth USD 0.46 billion on the way to USD 0.95 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

By 2034 the share stands at 5.5%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 31.97% of 2025 revenue in Capillary Electrophoresis, fastest growth of 14.58% in Next Generation Sequencing (NGS). The full report breaks Middle East and Africa out along every axis and by country.

30.43% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.14 billion, rising to USD 0.28 billion by 2034. It accounts for 30.43% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.46 billion in 2025 and USD 0.95 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Capillary Electrophoresis at 31.97% of 2025 revenue, easing to 28.02% by 2034, and the fastest is Next Generation Sequencing (NGS) at 14.58%, from 14.01% to 22%. Its 30.43% weight in Middle East and Africa means those movements carry straight into the regional totals. The full report reports Saudi Arabia by type separately.

In Saudi Arabia, forensic technologies and services operate under the oversight of the Ministry of Interior and its Public Security apparatus, which sets operational standards for criminal laboratories and evidence handling nationwide. Laboratories seeking formal recognition of their competence pursue accreditation through the Saudi Accreditation Center against international testing and calibration standards. Equipment sold into the market must meet conformity requirements administered by the Saudi Standards, Metrology and Quality Organization, and instruments overlapping with medical or diagnostic functions fall additionally under the Saudi Food and Drug Authority's device registration requirements. Because forensic evidence supports both criminal and civil proceedings under Sharia-influenced procedural law, suppliers are expected to show that their technologies meet recognised international methodological standards alongside domestic conformity certification.

In Saudi Arabia the field is Agilent Technologies, Promega, QIAGEN, LGC Forensics, MSAB, AB Sciex (Danaher Corporation), Eurofins Medigenomix GmbH, Forensics Consulting Solutions, Forensic Pathways, GE Healthcare Lifescience, LGC Limited, Neogen Corporation, NMS Labs, Pyramidal Technologies Ltd., SPEX Forensics and Thermo Fisher Scientific, Inc.. Capillary Electrophoresis, at 31.97% of 2025 revenue, is where the volume sits, and Next Generation Sequencing (NGS), growing at 14.58%, is where position changes hands over the forecast period. Weighting toward Middle East and Africa means competing for 5.86% of 2025 global revenue, a base of USD 0.46 billion moving to USD 0.95 billion across the forecast period.

South Africa is sized at USD 0.11 billion in 2025, rising to USD 0.22 billion by 2034; 1.4% of global revenue and 23.91% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, location, application, offering, end user, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.